1. Centers for Disease Control and Prevention Chronic kidney disease in the United States(2021).https://www.cdc.gov/kidneydisease/publications‐resources/ckd‐national‐facts.html. Accessed April 6 2021.
2. Centers for Disease Control and Prevention Chronic kidney disease risk factors and prevention(2021).https://www.cdc.gov/kidneydisease/publications‐resources/annual‐report/ckd‐risk‐prevention.html. Accessed April 6 2021.
3. US Food and Drug Administration Draft Guidance: Pharmacokinetics in patients with impaired renal function — study design data analysis and impact on dosing and labeling(2020).https://www.fda.gov/media/78573/download. Accessed April 6 2021.
4. European Medicines Agency Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function(2016).https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐evaluation‐pharmacokinetics‐medicinal‐products‐patients‐decreased‐renal‐function_en.pdf. Accessed April 6 2021.
5. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis